X-ZELL CEO to present at 2018 HealthInvestor Asia Summit
The TED-style presentation will give attendees a world-exclusive first look behind the scenes of X-ZELL’s revolutionary rare cell detection technology, with new insights into early prostate cancer detection that have never before been shared publicly.
Dr Bhakdi will also use the occasion to announce a game-changing new randomised controlled clinical trial to be carried out in collaboration with a world-famous health care organisation, and reflect on the need for more application- and outcome-based research in the biotechnology sector at large.
The HealthInvestor Asia Summit will be held at the Marina Bay Sands in Singapore on 15 May 2018.
Established in 2009 with investment from Vichit Suraphongchai – one of the leading figures in Southeast Asian banking – and material support from Thailand’s premier science university, Mahidol University, X-ZELL Inc. started out as a classic university spin-off.
It is the brainchild of Dr Sebastian Chakrit Punyaratabandhu Bhakdi, a German-Thai physician who was working in Bangkok on a fellowship from the German Research Foundation (GFR) when he came across a new way of magnetically separating malaria cells from a blood sample. Upon conclusion of his research, Dr Bhakdi continued to refine the technology and successfully applied it to cancer cell detection, which eventually led to the creation of X-ZELL Inc. The young company’s international breakthrough then came at Y Combinator’s W15 Winter Batch in early 2016, where it showcased a new way of reliably detecting ultra-rare CEC at an early stage – allowing physicians to diagnose malign cancer when it is still treatable. X-ZELL Inc. completed the program with a rare Honourable Mention and seed investment by various Silicon Valley-based angel investors, among them US start-up guru, Paul Buchheit – the creator and lead developer of Gmail. After returning to Bangkok, Dr Bhakdi fast-tracked the company’s corporate evolution with the opening of X-ZELL Inc.’s first overseas office in Sunnyvale, California, and the recruitment of key investor and COO, Johannes Hille, in early 2017. Since then, the company has launched myriad research projects and successfully brought its first commercial cancer test, X-ZELL Prostate™, to market in the Kingdom of Thailand.